Acute coronary syndromes
KEYWORDS: people, coronary, acute, pci, risk, acute coronary, therapy, recommendations, committee, evidence, angina, unstable, nstemi, unstable angina, offer

not intended to use GPI from the outset, but considers that clinical or angiographic features (such as worsening or persistent thrombus burden) have changed during the course of the procedure, such that there may be benefit to giving the patient GPI. Acute coronary syndromes (NG185) Recommendations for research The guideline committee has made the following recommendations for research. Key recommendations for research 1 Dual antiplatelet therapy for people aged 75 and over What is the most clinically and cost-effective dual antiplatelet therapy for people aged 75 and over with an acute coronary syndrome, who are having percutaneous coronary intervention (PCI)? [2020] Why this is important The evidence reviewed for this guideline found that prasugrel is the most clinically and cost-effective antiplatelet therapy when used with aspirin for the general acute coronary syndrome population having PCI, particularly for people with ST-segment elevation myocardial infarction (STEMI). However, the summary of product characteristics for prasugrel states that its use in people aged 75 and over 'is generally not recommended and should only be undertaken with caution after a careful individual benefit/risk evaluation by the prescribing physician indicates that benefits in terms of prevention of ischaemic events outweigh the risk of serious bleedings'. There
